Fig. 2: Recommendations for the treatment of patients with relapsed and/or refractory multiple myeloma at second line. | Nature Reviews Clinical Oncology

Fig. 2: Recommendations for the treatment of patients with relapsed and/or refractory multiple myeloma at second line.

From: EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Fig. 2

Recommendations include supporting levels of evidence and have been graded170 (Supplementary Table 1). aOnly in patients exposed to lenalidomide. Bela, belantamab mafodotin; cilta-cel, ciltacabtagene autoleucel; d, dexamethasone; Dara, daratumumab; Elo, elotuzumab; Isa, isatuximab; Ixa, ixazomib; K, carfilzomib; P, pomalidomide; R, lenalidomide; Sel, selinexor.

Back to article page